Data Registry in Chinese Hemophilia A and B Patients

Institute of Hematology & Blood Diseases Hospital, China200 enrolled

Overview

This is an open-label, prospective, multi-center, patient registry in Chinese Hemophilia A and B patients treated with anti-hemophilic coagulation factor replacement therapy.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Hemophilia A Hemophilia B

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria： Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study: 1. Hemophilia A and Hemophilia B patient diagnosed; 2. Taking anti-hemophilic coagulation factor replacement therapy during the 2 year registry period. Exclusion Criteria: 1\. Unwilling or unable to follow the terms of the protocol.

Locations (1)

Hospital of Blood disease

Tianjin, Tianjin Municipality, China

Outcomes

Primary Outcomes

The incidence of MIEs and other SAEs

The incidence of MIE(medically important events)s and other SAE(serious adverse event)s in the anti-hemophilic replacement treatment

Time frame: at the end of 2 year data registry

Secondary Outcomes

Treatment regimen

Treatment regimen of anti-hemophilic replacement treatment

Time frame: at the end of 2 year data registry

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.